Fig. 2: Kinetics of neutralizing antibody responses in SARS-CoV-2 infection.
a, Neutralizing antibody ID50 changes related to days POS. ID50 was measured using HIV-1-based virus particles (PVs), pseudotyped with the S glycoprotein of SARS-CoV-2. Each line represents one individual (n = 65). Severities 0–3 are shown in black and severities 4/5 in red. Pre-COVID-19 healthy control samples did not show any neutralization at a 1:20 serum dilution (Supplementary Table 3). A subset of neutralization experiments (n = 25) was conducted twice, yielding similar results. ID50 values for the remaining samples were measured once. b, Example kinetics of antibody responses (IgM, IgA, IgG binding to S glycoprotein, RBD and N protein, and ID50 against PVs and wild-type virus) for four individuals during acute infection and the convalescent phase. Graphs show comparison between disease-rated severity 0 (left) and disease-rated severity 4 (right). The cut-off for the pseudovirus and wild-type virus neutralization assays are 1:50 and 1:20, respectively.
